Nurse's Journey with Metastatic Triple-Negative Breast Cancer Highlights New Treatment Options and the Importance of Patient Advocacy

Vanessa, a travel nurse from Memphis, Tennessee, had her life meticulously planned: a thriving career, savings for a home, and a future she had worked hard to build. But everything changed when she was diagnosed with stage 3 triple-negative breast cancer, the most aggressive subtype. The diagnosis forced her to halt her ambitions and focus entirely on treatment. Even as a nurse, she found herself navigating unfamiliar territory. 'I've taken care of patients my whole life,' she says, 'but I didn't really know what breast cancer truly entailed.'

Treatment began quickly, but the cancer spread, leading to a metastatic triple-negative breast cancer diagnosis. 'When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,' she recalls. Triple-negative breast cancer tends to grow and spread faster than other types. For about half of women with metastatic triple-negative breast cancer, the first treatment may be the only chance to keep the cancer from growing, making initial choices critical. This subtype also occurs more often in younger women and appears at higher rates in Black and Hispanic women, underscoring the need for access to the latest education in these communities.

Historically, treatment options for metastatic triple-negative breast cancer were limited to chemotherapy, which impacts cancer cells more than normal cells. Vanessa's doctor suggested a clinical trial for a newer class of medicine called antibody-drug conjugates (ADCs). Unlike traditional chemotherapy, ADCs are designed to find specific markers and deliver medicines more directly to cancer cells. Until recently, ADCs were used later in treatment, but now they may be offered as a first-line therapy after diagnosis. Innovations like ADCs have already made a difference for many patients by helping to keep cancer from growing. For Vanessa, this means being able to plan ahead, knowing her good days and bad days—whether that's the next girls' trip or time with family.

However, not all ADCs are the same; safety and efficacy can vary. While not every patient will be eligible, understanding when they may be considered and how treatment can impact daily life can help patients feel more informed when discussing options with their care team. Vanessa's medical oncologist, Dr. Gregory Vidal, MD, PhD, Director of Clinical Research at West Cancer Center and Associate Professor at the University of Tennessee Health Science Center, emphasizes, 'When selecting treatment, it's important to consider patients' goals, wishes and needs so that we can try to realistically plan around those. All patients are different and may qualify for different ADCs.' Dr. Vidal encourages patients to have open conversations with their care team and ask questions, such as what treatment goals make the most sense at their stage of care.

Every person's experience is different, but many people living with metastatic breast cancer remain on treatment for life, aiming to manage the disease and slow progression while maintaining quality of life. Despite the physical and emotional toll, Vanessa persevered, leaning on close friends and family to keep 'faith over fear' by focusing on positives and planning outings around treatments. She encourages others to stay positive, ask questions, and advocate for themselves. 'You definitely have a fight in front of you, but you can get through this. You have to do your research and get answers,' she says.

To see how Vanessa and others navigate ADC treatment for metastatic triple-negative breast cancer, visit Expose-MBC.com/ADC.